codufilm
Guest
codufilm
Guest
Hello All --
Greetings from Berlin, Germany.
I am the producer of an upcoming feature documentary that looks at the pharmaceutical industry and the success of atypical antipsychotics, namely Zyprexa.
Though Lilly's past problems with Zyprexa (off-label use, downplaying of diabetes risk) has been well documented, we are hoping to dig a bit deeper into the Zyprexa story, in particular the results of early trials and the drug's dangerous side-effects, including sudden, unexpected death.
Please note that this isn't a "gotcha" documentary, nor is it a merely a piece of investigative journalism. The film (which has been fully funded through several EU public film funds) is in part a personal reflection of the filmmaker, who lost somebody close to her as a result of the medication she was taking for her schizophrenia.
In April of this year, Lilly lost its patent protection of Zyprexa. As Lilly's #1 selling drug, this change no doubt precipitated (in part at least) the many layoffs currently going on.
We're looking to speak to Lilly employees, past or present, who would be willing to talk to us about Zyprexa, its usage, testing, prescription, monitoring, and side effects.
Absolute discretion is guaranteed.
If interested, please contact us at codufilm@googlemail.com .
Please feel free to pass this note on to any potentially interested parties.
Thank you for you time.
codufilm@googlemail.com
Greetings from Berlin, Germany.
I am the producer of an upcoming feature documentary that looks at the pharmaceutical industry and the success of atypical antipsychotics, namely Zyprexa.
Though Lilly's past problems with Zyprexa (off-label use, downplaying of diabetes risk) has been well documented, we are hoping to dig a bit deeper into the Zyprexa story, in particular the results of early trials and the drug's dangerous side-effects, including sudden, unexpected death.
Please note that this isn't a "gotcha" documentary, nor is it a merely a piece of investigative journalism. The film (which has been fully funded through several EU public film funds) is in part a personal reflection of the filmmaker, who lost somebody close to her as a result of the medication she was taking for her schizophrenia.
In April of this year, Lilly lost its patent protection of Zyprexa. As Lilly's #1 selling drug, this change no doubt precipitated (in part at least) the many layoffs currently going on.
We're looking to speak to Lilly employees, past or present, who would be willing to talk to us about Zyprexa, its usage, testing, prescription, monitoring, and side effects.
Absolute discretion is guaranteed.
If interested, please contact us at codufilm@googlemail.com .
Please feel free to pass this note on to any potentially interested parties.
Thank you for you time.
codufilm@googlemail.com